Developer docs
API playgroundTry for free, no card

Search company profiles

Rivus Pharmaceuticals

Full company profile

uuid0000l2u

Namestring
Rivus Pharmaceuticals
Legal namestring
Rivus Pharmaceuticals, Inc.
Websiteurl
rivuspharma.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Rivus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing Controlled Metabolic Accelerators (CMAs), a class of oral small-molecule therapeutics that act by inducing controlled mitochondrial uncoupling to improve cellular metabolism. The company's lead candidate, HU6, is being advanced in parallel Phase 2/3 and Phase 2b programs for metabolic dysfunction-associated steatohepatitis (MASH, including the AMPLIFY and M-ACCEL trials), with earlier-stage work in heart failure with preserved ejection fraction (HFpEF, HuMAIN trial) and Type 2 diabetes. Across these programs, HU6 has demonstrated 30–40% liver fat reduction, meaningful body weight reductions (approximately 6 lbs at higher doses, approximately 10 lbs in patients with elevated HbA1c), and has now been administered to more than 500 patients, with results published in Lancet Gastroenterology & Hepatology, JAMA Cardiology, and the European Journal of Heart Failure.

The company is broadening its pipeline through RV-8451, an oral non-peptide GLP-1 receptor agonist in IND-enabling preclinical development with a targeted IND submission in Q1 2027, positioning Rivus within the high-value oral incretin category. The company is headquartered in Charlottesville, Virginia, with a second operational site opened in South San Francisco in April 2025, and operates with a headcount of approximately 11–50 employees under a leadership team drawn from Vertex Pharmaceuticals, Genentech/Roche, Aimmune, J&J, GSK, and other major biopharma organizations.

As a pre-revenue, venture-backed private company, Rivus generates no commercial revenue and operates on equity capital, with cumulative disclosed financing of approximately $290M across a 2021 Series A ($35M), 2022 Series B ($132M, led by RA Capital with Bain Capital Life Sciences and BB Biotech AG), and subsequent 2024 and 2025 rounds totaling roughly $123M. Future revenue mechanics will depend on either direct commercialization of an approved CMA product, partnership/out-licensing arrangements, or both, though no commercial deals have been disclosed. The company targets large cardiometabolic markets — obesity affects approximately 1 billion individuals globally and MASH affects more than 5% of the U.S. adult population — offering substantial long-term commercial upside if clinical and regulatory milestones are achieved.

Short descriptiontext

Rivus Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral small-molecule Controlled Metabolic Accelerators (CMAs) that leverage mitochondrial uncoupling to treat cardiometabolic diseases, with lead candidate HU6 in Phase 2/3 for MASH and HFpEF.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCharlottesville, United States
HQ citystring
Charlottesville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiometabolic therapeutics, mitochondrial uncoupling drugs, MASH oral therapy, obesity small molecule, HFpEF treatment
Industry4 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cardiometabolic Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development and Commercialization
TypeOne Time License
Description

Rivus Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel oral medicines for cardiometabolic diseases. The company is focused on advancing HU6 in Phase 2/3 clinical trials for MASH and HFpEF, with plans to commercialize its therapies upon regulatory approval. Revenue will be generated through product sales upon FDA approval.

rivuspharma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Rivus Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel oral small molecule medicines for cardiometabolic diseases based on its proprietary Controlled Metabolic Accelerators (CMAs) platform. Its lead candidate, HU6, is an oral once-daily CMA that increases energy expenditure through mitochondrial uncoupling to deliver fat-selective weight loss while preserving muscle mass, currently advancing in Phase 2 trials for MASH, HFpEF, and Type 2 diabetes/obesity. The pipeline also includes RV-8451, the industry's first muscle-preserving oral GLP-1 non-peptide agonist in IND-enabling studies for obesity.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Liver fat reduction of 30-40% across doses in Phase 2a trials (p<0.0001)
+5 more records
Product overview1 text field

Rivus Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of oral medicines for cardiometabolic diseases. The core technology platform is Controlled Metabolic Accelerators (CMAs), a new class of small molecule therapeutics that increase energy expenditure through mitochondrial uncoupling. The lead product is HU6, an oral therapy advancing in Phase 2 trials for MASH (AMPLIFY trial) and previously studied in HFpEF (HuMAIN trial) and obesity/MASLD. The pipeline also includes RV-8451, an oral GLP-1 non-peptide agonist in IND-enabling studies for obesity. Both products are designed to deliver fat-selective weight loss while preserving muscle mass, addressing key limitations of existing GLP-1 therapies.

Product and service2 records
1HU6
CategoryClinical-stage cardiometabolic drug candidate
Description

HU6 is Rivus Pharmaceuticals' lead clinical-stage drug candidate — an oral, once-daily small molecule Controlled Metabolic Accelerator (CMA) that increases energy expenditure through mitochondrial uncoupling to promote fat-selective weight loss while preserving muscle mass. It is being developed for MASH (in the Phase 2 AMPLIFY trial), HFpEF (in the HuMAIN Phase 2a trial), Type 2 diabetes with obesity at risk of MASH (in the Phase 2b M-ACCEL trial), and obesity, with over 500 patients treated across Phase 2 trials.

2RV-8451
CategoryClinical-stage obesity drug candidate (GLP-1)
Description

RV-8451 is described as the industry's first muscle-preserving oral GLP-1 non-peptide agonist — a highly differentiated oral GLP-1 therapy designed to deliver fat-specific, durable weight loss with convenient oral dosing for the treatment of obesity. It is currently in IND-enabling studies with planned IND submission targeted for Q1 2027.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Eli Lilly is the dominant incumbent in cardiometabolic disease with Zepbound/Mounjaro (tirzepatide), and is advancing orforglipron (oral GLP-1) and other assets in obesity, MASH, and HFpEF. It sets the competitive benchmark Rivus must beat on efficacy, dosing convenience, and commercial reach.

TypeDirect peer
Description

Viking is advancing oral and injectable therapies for obesity and MASH, including VK2735 (GLP-1/GIP) and an oral formulation. It is a direct competitor to Rivus's HU6 and RV-8451 in the obesity/MASH overlap.

TypeDirect peer
Description

Akero is developing efruxifermin (FGF21 analog) for MASH, a competing mechanism to Rivus's mitochondrial uncoupling. Both are clinical-stage companies targeting the same high-prevalence liver disease with disease-modifying claims.

TypeDirect peer
Description

Structure Therapeutics is developing oral small molecules targeting GLP-1R for obesity and related cardiometabolic indications, directly comparable to Rivus's oral RV-8451 GLP-1 non-peptide agonist program.

TypeEmerging player
Description

Terns is developing oral small molecule therapies for obesity and MASH, including TERN-501 (THR-β agonist) and an oral GLP-1. It is an emerging peer pursuing oral, muscle-friendly weight loss and liver-disease indications.

TypeBroad incumbent
Description

Novo Nordisk is the GLP-1 category creator (Ozempic, Wegovy) and is actively expanding into MASH, HFpEF, and other cardiometabolic indications. Its commercial infrastructure and pipeline breadth define the realistic competitive ceiling for Rivus.

TypeDirect peer
Description

Inventiva is developing lanifibranor, an oral pan-PPAR agonist for MASH. It is a clinical-stage peer competing for the same oral MASH market with a differentiated but overlapping mechanism.

TypeEmerging player
Description

Altimmune is developing pemvidutide, a GLP-1/glucagon dual agonist for obesity and MASH. It is a clinical-stage peer focused on the same cardiometabolic indications, with a different but overlapping mechanism.

TypeDirect peer
Description

89bio is developing pegozafermin for MASH, another direct competitor in the cardiometabolic liver disease space. Like Rivus, it is a clinical-stage biotech pursuing fibrosis improvement in MASH patients.

TypeDirect peer
Description

Madrigal developed Rezdiffra, the first FDA-approved oral therapy for MASH. It is the closest direct competitor to Rivus in the oral MASH space and a benchmark for clinical, regulatory, and commercial execution in this indication.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rivus Pharmaceuticals

Cardiometabolic Biopharmaceuticalsrivuspharma.com

Rivus Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral small-molecule Controlled Metabolic Accelerators (CMAs) that leverage mitochondrial uncoupling to treat cardiometabolic diseases, with lead candidate HU6 in Phase 2/3 for MASH and HFpEF.

What Rivus Pharmaceuticals does

Rivus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing Controlled Metabolic Accelerators (CMAs), a class of oral small-molecule therapeutics that act by inducing controlled mitochondrial uncoupling to improve cellular metabolism. The company's lead candidate, HU6, is being advanced in parallel Phase 2/3 and Phase 2b programs for metabolic dysfunction-associated steatohepatitis (MASH, including the AMPLIFY and M-ACCEL trials), with earlier-stage work in heart failure with preserved ejection fraction (HFpEF, HuMAIN trial) and Type 2 diabetes. Across these programs, HU6 has demonstrated 30–40% liver fat reduction, meaningful body weight reductions (approximately 6 lbs at higher doses, approximately 10 lbs in patients with elevated HbA1c), and has now been administered to more than 500 patients, with results published in Lancet Gastroenterology & Hepatology, JAMA Cardiology, and the European Journal of Heart Failure.

The company is broadening its pipeline through RV-8451, an oral non-peptide GLP-1 receptor agonist in IND-enabling preclinical development with a targeted IND submission in Q1 2027, positioning Rivus within the high-value oral incretin category. The company is headquartered in Charlottesville, Virginia, with a second operational site opened in South San Francisco in April 2025, and operates with a headcount of approximately 11–50 employees under a leadership team drawn from Vertex Pharmaceuticals, Genentech/Roche, Aimmune, J&J, GSK, and other major biopharma organizations.

As a pre-revenue, venture-backed private company, Rivus generates no commercial revenue and operates on equity capital, with cumulative disclosed financing of approximately $290M across a 2021 Series A ($35M), 2022 Series B ($132M, led by RA Capital with Bain Capital Life Sciences and BB Biotech AG), and subsequent 2024 and 2025 rounds totaling roughly $123M. Future revenue mechanics will depend on either direct commercialization of an approved CMA product, partnership/out-licensing arrangements, or both, though no commercial deals have been disclosed. The company targets large cardiometabolic markets — obesity affects approximately 1 billion individuals globally and MASH affects more than 5% of the U.S. adult population — offering substantial long-term commercial upside if clinical and regulatory milestones are achieved.

Rivus Pharmaceuticals firmographics

Firmographics
Name
Rivus Pharmaceuticals
Legal name
Rivus Pharmaceuticals, Inc.
Website
https://rivuspharma.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Rivus Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral small-molecule Controlled Metabolic Accelerators (CMAs) that leverage mitochondrial uncoupling to treat cardiometabolic diseases, with lead candidate HU6 in Phase 2/3 for MASH and HFpEF.
Ownership category
akta.pro rank

Rivus Pharmaceuticals industry classification

Industry
Product category
Cardiometabolic Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals

Keywords

  • Cardiometabolic therapeutics
  • Mitochondrial uncoupling drugs
  • MASH oral therapy
  • Obesity small molecule
  • HFpEF treatment

Where Rivus Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Charlottesville
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Rivus Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Development and Commercialization: Rivus Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel oral medicines for cardiometabolic diseases. The company is focused on advancing HU6 in Phase 2/3 clinical trials for MASH and HFpEF, with plans to commercialize its therapies upon regulatory approval. Revenue will be generated through product sales upon FDA approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Rivus Pharmaceuticals product offering

Product offering

Core offering

Rivus Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel oral small molecule medicines for cardiometabolic diseases based on its proprietary Controlled Metabolic Accelerators (CMAs) platform. Its lead candidate, HU6, is an oral once-daily CMA that increases energy expenditure through mitochondrial uncoupling to deliver fat-selective weight loss while preserving muscle mass, currently advancing in Phase 2 trials for MASH, HFpEF, and Type 2 diabetes/obesity. The pipeline also includes RV-8451, the industry's first muscle-preserving oral GLP-1 non-peptide agonist in IND-enabling studies for obesity.

Product overview

Rivus Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of oral medicines for cardiometabolic diseases. The core technology platform is Controlled Metabolic Accelerators (CMAs), a new class of small molecule therapeutics that increase energy expenditure through mitochondrial uncoupling. The lead product is HU6, an oral therapy advancing in Phase 2 trials for MASH (AMPLIFY trial) and previously studied in HFpEF (HuMAIN trial) and obesity/MASLD. The pipeline also includes RV-8451, an oral GLP-1 non-peptide agonist in IND-enabling studies for obesity. Both products are designed to deliver fat-selective weight loss while preserving muscle mass, addressing key limitations of existing GLP-1 therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • HU6 HU6 is Rivus Pharmaceuticals' lead clinical-stage drug candidate — an oral, once-daily small molecule Controlled Metabolic Accelerator (CMA) that increases energy expenditure through mitochondrial uncoupling to promote fat-selective weight loss while preserving muscle mass. It is being developed for MASH (in the Phase 2 AMPLIFY trial), HFpEF (in the HuMAIN Phase 2a trial), Type 2 diabetes with obesity at risk of MASH (in the Phase 2b M-ACCEL trial), and obesity, with over 500 patients treated across Phase 2 trials.
  • RV-8451 RV-8451 is described as the industry's first muscle-preserving oral GLP-1 non-peptide agonist — a highly differentiated oral GLP-1 therapy designed to deliver fat-specific, durable weight loss with convenient oral dosing for the treatment of obesity. It is currently in IND-enabling studies with planned IND submission targeted for Q1 2027.

Quantifiable outcome

  • Liver fat reduction of 30-40% across doses in Phase 2a trials (p<0.0001)
  • +5 more outcomes

Companies that use Rivus Pharmaceuticals

Customer profile

Segments4 records

Ideal customer profiles4 records

Rivus Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Rivus Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Rivus Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Eli Lilly: Eli Lilly is the dominant incumbent in cardiometabolic disease with Zepbound/Mounjaro (tirzepatide), and is advancing orforglipron (oral GLP-1) and other assets in obesity, MASH, and HFpEF. It sets the competitive benchmark Rivus must beat on efficacy, dosing convenience, and commercial reach.
  • Novo Nordisk: Novo Nordisk is the GLP-1 category creator (Ozempic, Wegovy) and is actively expanding into MASH, HFpEF, and other cardiometabolic indications. Its commercial infrastructure and pipeline breadth define the realistic competitive ceiling for Rivus.

Direct peers

  • Viking Therapeutics: Viking is advancing oral and injectable therapies for obesity and MASH, including VK2735 (GLP-1/GIP) and an oral formulation. It is a direct competitor to Rivus's HU6 and RV-8451 in the obesity/MASH overlap.
  • Akero Therapeutics: Akero is developing efruxifermin (FGF21 analog) for MASH, a competing mechanism to Rivus's mitochondrial uncoupling. Both are clinical-stage companies targeting the same high-prevalence liver disease with disease-modifying claims.
  • Structure Therapeutics: Structure Therapeutics is developing oral small molecules targeting GLP-1R for obesity and related cardiometabolic indications, directly comparable to Rivus's oral RV-8451 GLP-1 non-peptide agonist program.
  • Inventiva: Inventiva is developing lanifibranor, an oral pan-PPAR agonist for MASH. It is a clinical-stage peer competing for the same oral MASH market with a differentiated but overlapping mechanism.
  • 89bio: 89bio is developing pegozafermin for MASH, another direct competitor in the cardiometabolic liver disease space. Like Rivus, it is a clinical-stage biotech pursuing fibrosis improvement in MASH patients.
  • Madrigal Pharmaceuticals: Madrigal developed Rezdiffra, the first FDA-approved oral therapy for MASH. It is the closest direct competitor to Rivus in the oral MASH space and a benchmark for clinical, regulatory, and commercial execution in this indication.

Emerging players

  • Terns Pharmaceuticals: Terns is developing oral small molecule therapies for obesity and MASH, including TERN-501 (THR-β agonist) and an oral GLP-1. It is an emerging peer pursuing oral, muscle-friendly weight loss and liver-disease indications.
  • Altimmune: Altimmune is developing pemvidutide, a GLP-1/glucagon dual agonist for obesity and MASH. It is a clinical-stage peer focused on the same cardiometabolic indications, with a different but overlapping mechanism.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Rivus Pharmaceuticals social profiles

Digital presence

Rivus Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rivus Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles10 records

Rivus Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rivus Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rivus Pharmaceuticals

What does Rivus Pharmaceuticals do?

Rivus Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel oral small molecule medicines for cardiometabolic diseases based on its proprietary Controlled Metabolic Accelerators (CMAs) platform. Its lead candidate, HU6, is an oral once-daily CMA that increases energy expenditure through mitochondrial uncoupling to deliver fat-selective weight loss while preserving muscle mass, currently advancing in Phase 2 trials for MASH, HFpEF, and Type 2 diabetes/obesity. The pipeline also includes RV-8451, the industry's first muscle-preserving oral GLP-1 non-peptide agonist in IND-enabling studies for obesity.

Is Rivus Pharmaceuticals a public or private company?

Rivus Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Rivus Pharmaceuticals founded?

Rivus Pharmaceuticals was founded in 2021. It employs 11 to 50 people.

Where is Rivus Pharmaceuticals based?

Rivus Pharmaceuticals is headquartered in Charlottesville, United States, in the North America region.

How does Rivus Pharmaceuticals make money?

One revenue line is on record: pharmaceutical Development and Commercialization.

Who are Rivus Pharmaceuticals's main competitors?

Broad incumbents on record are Eli Lilly and Novo Nordisk. Direct peers are Viking Therapeutics, Akero Therapeutics, Structure Therapeutics, Inventiva, 89bio and Madrigal Pharmaceuticals. Emerging players are Terns Pharmaceuticals and Altimmune.

Does Rivus Pharmaceuticals have an API?

No public API is recorded for Rivus Pharmaceuticals.

What industry is Rivus Pharmaceuticals in?

Rivus Pharmaceuticals's product category is Cardiometabolic Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIACAE, Gastroenterology Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyRivus to show animal data on muscle-sparing GLP-1Rivus Pharmaceuticals will present preclinical data on its oral GLP-1 agonist RV-8451 at ObesityWeek 2026 in Washington, DC, on November 14-17. The company claims the drug preserves muscle while driving fat-specific weight loss in animal models, and plans to file an IND for chronic weight management in the first quarter of 2027.Longevity.TechnologyRivus to present data on new oral weight-loss drug that targets fat while saving muscleRivus Pharmaceuticals will present preclinical data for its oral GLP-1 agonist RV-8451 at ObesityWeek 2026, including head-to-head comparisons and fat-specific weight loss. The company plans to submit an investigational new drug application in the first quarter of 2027 to advance RV-8451 into Phase 1 clinical testing.Business & FinancialRivus Pharmaceuticals To Present Preclinical Obesity Data For Muscle-Preserving, Oral GLP-1 RV-8451 At Obesityweek®Rivus Pharmaceuticals will present preclinical data for its oral GLP-1 RV-8451 at ObesityWeek in November 2026, highlighting muscle preservation. The company plans to submit an IND for chronic weight management in the first quarter of 2027.HCP LiveOral HU6 Shows Fat-Selective Weight Loss in MASH, With Mazen Noureddin, MDRivus Pharmaceuticals announced on April 14, 2026, that the first patients had been dosed in the phase 2 AMPLIFY trial evaluating HU6 for metabolic dysfunction-associated steatohepatitis (MASH). The oral therapy utilizes a mitochondrial uncoupling mechanism to achieve fat-selective weight loss and significant liver fat reduction while preserving skeletal muscle mass. Top-line data from the study are expected in mid-2027 to inform future late-stage development.HCP LiveUnderstanding HU6 and Its Emerging Role in MASH, With Mazen Noureddin, MD, MHScRivus Pharmaceuticals presented positive phase 2 data for its investigational drug HU6 at the AASLD The Liver Meeting 2025, demonstrating significant reductions in liver fat and body weight in patients with metabolic dysfunction-associated steatohepatitis (MASH). The trial met its primary endpoint, showing that HU6 selectively reduced visceral fat while preserving muscle mass, with a favorable safety profile and minimal gastrointestinal side effects. These findings support the potential of HU6 as a standalone or adjunct therapy for MASH treatment.BioWorldANT-activating uncoupler RV-202 drives selective fat loss in obese miceRivus Pharmaceuticals researchers presented preclinical efficacy data on RV-202, a novel oral mitochondrial uncoupler with ANT-activating activity, in obesity models. The data showed selective fat loss in obese mice. No further details were disclosed.BioWorldRivus’ GLP-1RA leads to fat-selective weight loss with lean mass preservationRivus Pharmaceuticals' oral, nonpeptide GLP-1RA RV-8451 is being developed to promote weight loss while preserving lean mass. The company's preclinical profile suggests fat-selective weight loss, addressing limitations of existing GLP-1RAs.BioSpaceRivus Pharmaceuticals Announces Preclinical Data for RV-8451, a Muscle-Preserving, Oral GLP-1, at ADA 2026 Scientific SessionsRivus Pharmaceuticals announced preclinical data for RV-8451, an oral GLP-1 agonist, at ADA 2026, showing fat-selective weight loss while preserving lean mass in diet-induced obese non-human primates. The company plans to submit an IND for obesity in Q1 2027.GlobeNewswireRivus Pharmaceuticals Announces Preclinical Data for RV-8451, a Muscle-Preserving, Oral GLP-1, at ADA 2026 Scientific SessionsRivus Pharmaceuticals announced preclinical data for RV-8451, a muscle-preserving oral GLP-1 receptor agonist, at the ADA 2026 Scientific Sessions in New Orleans. In diet-induced obese non-human primates, RV-8451 produced up to 20% fat mass reduction while preserving lean mass, with a head-to-head study showing greater fat loss compared to orforglipron (30% vs 11%) and improved lean mass preservation. The company is advancing IND-enabling studies with an IND submission targeted for Q1 2027.Clinical Trials ArenaRivus Pharmaceuticals begins patient dosing in Phase II AMPLIFY trialRivus Pharmaceuticals began dosing the first patients in the AMPLIFY Phase II trial of HU6, an oral therapy for MASH. The double-blind, placebo-controlled trial enrolls about 180 adults with F2/F3 MASH, with a primary endpoint of liver fat reduction. Data from the Phase IIa HuMAIN trial showed significant liver fat reductions and favorable safety.